Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 9
1957 1
1958 2
1959 6
1961 10
1962 3
1963 9
1964 6
1965 2
1966 8
1969 4
1971 3
1972 2
1975 1
1976 1
1978 2
1979 1
1980 1
1981 4
1982 1
1983 7
1984 7
1985 4
1986 8
1987 4
1988 5
1989 8
1990 6
1991 11
1992 10
1993 13
1994 10
1995 5
1996 12
1997 10
1998 8
1999 10
2000 9
2001 6
2002 13
2003 14
2004 5
2005 10
2006 12
2007 6
2008 7
2009 8
2010 12
2011 10
2012 5
2013 11
2014 12
2015 15
2016 13
2017 12
2018 7
2019 5
2020 11
2021 11
2022 12
2023 9
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

432 results

Results by year

Filters applied: . Clear all
Page 1
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. Flaig TW, et al. Among authors: pagliaro lc. J Natl Compr Canc Netw. 2022 Aug;20(8):866-878. doi: 10.6004/jnccn.2022.0041. J Natl Compr Canc Netw. 2022. PMID: 35948037
Platinum-based chemotherapy for variant castrate-resistant prostate cancer.
Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Aparicio AM, et al. Among authors: pagliaro lc. Clin Cancer Res. 2013 Jul 1;19(13):3621-30. doi: 10.1158/1078-0432.CCR-12-3791. Epub 2013 May 6. Clin Cancer Res. 2013. PMID: 23649003 Free PMC article.
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, Price KA, Molina JR, Pagliaro LC, Halfdanarson TR, Grothey A, Markovic SN, Nowakowski GS, Ansell SM, Wang ML. Wang Y, et al. Among authors: pagliaro lc. JAMA Oncol. 2019 Jul 1;5(7):1008-1019. doi: 10.1001/jamaoncol.2019.0393. JAMA Oncol. 2019. PMID: 31021376 Free PMC article.
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A. Flaig TW, et al. Among authors: pagliaro lc. J Natl Compr Canc Netw. 2020 Mar;18(3):329-354. doi: 10.6004/jnccn.2020.0011. J Natl Compr Canc Netw. 2020. PMID: 32135513
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).
Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, McKay RR, Singh P, Pagliaro L, Dreicer R, Srinivas S, Loriot Y, Vaishampayan U, Goel S, Curran D, Panneerselvam A, Schwickart M, Choueiri TK, Pal S. Agarwal N, et al. Among authors: pagliaro l. Lancet Oncol. 2022 Jul;23(7):899-909. doi: 10.1016/S1470-2045(22)00278-9. Epub 2022 Jun 9. Lancet Oncol. 2022. PMID: 35690072 Clinical Trial.
Reply by Authors.
Azizi M, Aydin AM, Hajiran A, Lai A, Kumar A, Peyton CC, Minhas S, Sonpavde GP, Chahoud J, Pagliaro LC, Necchi A, Spiess PE. Azizi M, et al. Among authors: pagliaro lc. J Urol. 2020 Jun;203(6):1155. doi: 10.1097/JU.0000000000000746.03. Epub 2020 Mar 16. J Urol. 2020. PMID: 32176595 No abstract available.
Radiation Therapy in Oligometastatic Prostate Cancer.
Chinniah S, Stish B, Costello BA, Pagliaro L, Childs D, Quevedo F, Lucien F, Bryce A, Park SS, Orme JJ. Chinniah S, et al. Among authors: pagliaro l. Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):684-692. doi: 10.1016/j.ijrobp.2022.07.014. Epub 2022 Jul 22. Int J Radiat Oncol Biol Phys. 2022. PMID: 35878715 Free article. Review.
Bladder cancer.
Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M; National Comprehensive Cancer Network (NCCN). Clark PE, et al. Among authors: pagliaro lc. J Natl Compr Canc Netw. 2013 Apr 1;11(4):446-75. doi: 10.6004/jnccn.2013.0059. J Natl Compr Canc Netw. 2013. PMID: 23584347
432 results